Atopic dermatitis, psoriasis, and hidradenitis suppurativa (HS) can present differently in diverse patients, potentially leading to delayed diagnosis and therefore delayed treatment, explained James Song, MD, director of clinical research and associate chief medical officer at Frontier Dermatology.
James Song, MD, director of clinical research and associate chief medical officer at Frontier Dermatology, highlights key insights from his 2023 Fall Clinical Dermatology Conference session about recognizing how atopic dermatitis, psoriasis, and hidradenitis suppurativa (HS) affect people differently based on severity and skin tone.
Song co-presented the session with Andrew Alexis, MD, MPH, Andrew Alexis, MD, MPH, FAAD, vice chair for diversity and inclusion for the Department of Dermatology and a dermatologist at the Center for Diverse Skin Complexions at Weill Cornell Medicine in New York City; and Linda Stein Gold, MD, director of Dermatology Clinical Research at Henry Ford Health System.
He explained that there are different presentations of skin diseases in patients who have darker skin, and not having a clear understanding of these differences can result in both a delay in diagnosis and a delay in treatment start.
In addition, patient with skin of color often present with more advanced disease. In a disease like psoriasis, this may not be a problem because there are so many therapies available that can effectively treat the disease. However, with HS, medications don't work as well once the patient has advanced enough to develop tunnels or scarring.
According to Song, patients with skin of color have to get to a dermatologist earlier when there is a better window of opportunity to intervene for the best response to treatment.
In addition to HS being more common in Black and Latinx patients, there is also a disproportionately higher number of patients with skin of color who have severe disease, which is tied to their social determinants of health, he said. They may not have access to specialists or newer medications. They may have lower health literacy. Or due to historical injustices by the medical system, they may simply not trust the system anymore.
Stuck in Prior Auth Purgatory: The Hidden Costs of Health Care Delays
June 19th 2025Delays, denials, and endless paperwork—prior authorization isn’t just a headache for providers; it’s a barrier for patients who need timely care, explains Colin Banas, MD, MHA, chief medical officer with DrFirst.
Listen
Targeting the Root of gMG With Inebilizumab: A Q&A With Richard Nowak, MD, MS
June 24th 2025In this interview, Richard J. Nowak, MD, MS, principal investigator of the MINT trial of inebilizumab for generalized myasthenia gravis (gMG), discusses the trial’s key findings, including significant improvements in patient- and physician-assessed outcomes, as well as longer-term implications and future areas of investigation.
Read More